In animal models of AAA, inhibition of CXCR1/2 receptors for IL-8 caused reduced aneurysm growth; therefore, targeting the signaling pathway of this cytokine could be a promising strategy for AAA therapy [34]. Here, CXCL8 is linked to triple-A syndrome.